potentially modest GLP-1 support based on early studies, but not confirmed in humans
Conclusion Managing DKD requires a multifaceted approach, starting with lifestyle advice, addressing the CV risk factors of hypertension and dyslipidaemia, treating hyperglycaemia, and harnessing the cardiorenal protective properties of specific drugs
Recent employer surveys show: 19% of employers with 200+ employees cover GLP-1s for weight loss 43% of employers with 5,000+ employees provide coverage 64% of employers with 20,000+ employees offer coverage Large employers are increasingly viewing obesity as a chronic condition requiring long-term treatment strategies rather than short-term interventions
Key examples include: Semaglutide (Ozempic, Wegovy): A onceweekly injection
Brand Origin: Japan
Alternative Treatments for IBS in the UK NICE recommends a stepwise approach to IBS management , beginning with lifestyle modifications and progressing to pharmacological interventions based on symptom severity and predominant subtype